Background: Hormone-sensitive prostate cancer (HSPC) and castration-resistant prostate cancer (CRPC) are two distinct forms of prostate cancer that are distinguished by their reactions to hormonal therapy. In general, patients with cancer who seek treatment at CRPC do not survive. The management of CRPC currently involves the use of androgen deprivation therapy (ADT), PC vaccination, chemotherapy, anti-androgen therapy, radionuclide therapy, immunotherapy, and targeted medications, including poly (ADP-ribose) polymerase (PARP) inhibitors. Objectives: The objective of this investigation is to determine the safety and efficacy of PARP inhibitors in the treatment of prostate cancer. Methods: This study established the adherence to all criteria by comparing it to the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) 2020 standards. Consequently, the experts were able to guarantee that the research was current. This search strategy considered publications published between 2013 and 2023 in order to obtain these results. This objective was accomplished by employing a variety of online reference sources, including Pubmed and SagePub. Review articles, works that had been previously published, and works that were only partially completed were excluded.Result: As a result of our inquiry, we obtained 38 publications from the PubMed database and 173 entries from SagePub. In total, the search yielded 37 articles indexed in SagePub and 54 articles indexed in PubMed for the year 2013. The title screening produced a total of 25 articles for PubMed and 17 articles for SagePub. Ultimately, a total of ten documents were assembled. Five investigations that satisfied the specified criteria were included. Conclusion: The safety and efficacy of PARP medications as monotherapy in mCRPC patients with BRCA 1/2 gene mutations or HRR-related gene mutations. As part of an ongoing, comprehensive investigation into PARP inhibitors, over eighty PARP inhibitor therapy trials have been conducted in PC patients, involving a variety of monotherapies and combination regimens.